Nutritional Prognostic Factors in ALS (PEG-ALS)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03487536 |
|
Recruitment Status :
Completed
First Posted : April 4, 2018
Last Update Posted : April 5, 2018
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Background. Several nutritional factors have been evaluated as prognostic factors for survival in ALS patients at earlier stages of the disease [body mass index (BMI), body composition expressed as fat free mass (FFM), fat mass (FM), phase angle (PhA), low-density lipoprotein/high-density lipoprotein (LDL/HDL) ratio, cholesterol levels], while only two studies have evaluated some of these parameters after PEG placement.
Aim. BMI and cholesterol levels were evaluated as prognostic factors for survival after percutaneous endoscopic gastrostomy (PEG) placement Moreover, the relationship between body composition and BMI in a subgroup of ALS patients was evaluated.
| Condition or disease | Intervention/treatment |
|---|---|
| Nutritional Deficiency Neuro-Degenerative Disease Gastrostomy | Other: Nutritional assessment |
| Study Type : | Observational |
| Actual Enrollment : | 47 participants |
| Observational Model: | Case-Only |
| Time Perspective: | Prospective |
| Official Title: | Nutritional Prognostic Factors in Patients With Amyotrophic Lateral Sclerosis and Percutaneous Endoscopic Gastrostomy |
| Actual Study Start Date : | January 2, 2006 |
| Actual Primary Completion Date : | June 30, 2015 |
| Actual Study Completion Date : | July 31, 2016 |
- Other: Nutritional assessment
BMI and cholesterol levels evaluation
- nutritional assessment [ Time Frame: at the time of PEG placement (one day) ]Weight and height (combined to report BMI in kg/m^2)
- biochemical nutritional assessment [ Time Frame: only at the time of PEG placement (one day) ]cholesterol levels
- body composition assessment [ Time Frame: within 2 months from the PEG implantation (one day) ]Evaluation of fat mass and fat free mass
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | Child, Adult, Older Adult |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Probability Sample |
Inclusion Criteria:
- ALS patients who underwent PEG tube placement from 2006 to 2015 and were referred to the artificial nutrition team of the Gastroenterology Unit
Exclusion Criteria:
- ALS patients without PEG
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03487536
| Italy | |
| Policlinic Hospital | |
| Bari, Italy, 70124 | |
| Principal Investigator: | Michele Barone | University of Bari |
| Responsible Party: | Michele Barone, Researcher, University of Bari |
| ClinicalTrials.gov Identifier: | NCT03487536 |
| Other Study ID Numbers: |
Policlinic Hospital 2, Bari |
| First Posted: | April 4, 2018 Key Record Dates |
| Last Update Posted: | April 5, 2018 |
| Last Verified: | April 2018 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | Undecided |
| Plan Description: | the results have not yet been shared with all the authors |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
|
Neurodegenerative Diseases Malnutrition Nutrition Disorders Nervous System Diseases |

